NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...

Boundless Bio has announced a strategic portfolio prioritization aimed at optimizing its oncology programs, particularly focusing on the combination therapy of BBI-355 and BBI-825, alongside a new ...

Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and ...

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose ...

The work of portfolio analysis is becoming ever more demanding. The volume and complexity of the tasks required to create, analyze, edit and report on investment portfolios is rising rapidly.

- PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other ...

– Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases – – ...

Genmab A/S(Nasdaq: GMAB) announced today thatit will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating ...